Abstract
The diverse roles of the hormone oxytocin in physiological homeostasis, milk let-down, maternal and social affiliative behaviors, emotion regulation, and cognition have been studied across various disciplines.1 Among them, preclinical studies have demonstrated an effect of oxytocin on ingestive behaviors. In this issue of NEJM Evidence, Plessow et al.2 report results of a well-designed, randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of intranasal oxytocin (24 IU daily in divided doses) on weight loss in participants who are obese. Despite extensive preclinical studies demonstrating that oxytocin reduces food intake3 and preliminary clinical trials supporting the potential use of oxytocin as an antiobesity medication in humans.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
